Hipoksija tumora i radiorezistentnost
DOI:
https://doi.org/10.55378/rv.48.2.6Ključne riječi:
Tumorska hipoksija, radiorezistentnost, faktori inducirani hipoksijom (HIF), radioterapija, omjer povećanja kisika (OER)Sažetak
Tumorska hipoksija predstavlja čestu karakteristiku solidnih tumora, značajno pridonoseći povećanoj agresivnosti tumora, njegovom metastatskom potencijalu i otpornosti na konvencionalne terapije poput radioterapije. Ovaj pregled analizira složenu povezanost između tumorske hipoksije i radiorezistentnosti, ističući molekularne mehanizme koji sudjeluju u tom procesu te potencijalne terapijske strategije usmjerene na povećanje učinkovitosti radioterapije kod hipoksičnih tumora. Ključni mehanizmi uključuju ulogu faktora induciranih hipoksijom (HIF), s posebnim naglaskom na HIF-1α, koji regulira brojne gene uključene u preživljavanje, proliferaciju i otpornost tumora u uvjetima hipoksije. U pregledu se također raspravlja o omjeru povećanja kisika (OER) i njegovom utjecaju na ishode radioterapije, naglašavajući kako hipoksija smanjuje radiosenzitivnost ograničavanjem nastanka oštećenja DNA izazvanih zračenjem. Unatoč razvoju različitih strategija za suzbijanje radiootpornosti uzrokovane hipoksijom, poput inhibitora HIF-a, genske terapije ciljane na hipoksične stanice i pro-lijekova aktiviranih hipoksijom (HAPs), klinički rezultati su često neujednačeni, što ukazuje na potrebu za dodatnim istraživanjima. Osim toga, pregledava se napredak u tehnikama snimanja za detekciju tumorske hipoksije, što bi moglo omogućiti preciznije i personaliziranije pristupe radioterapiji, poput „dose painting“ metode. Budući napori u prevladavanju tumorske hipoksije u kontekstu radioterapije usmjerit će se prema integraciji inovativnih terapijskih strategija, personalizirane medicine i naprednih tehnologija snimanja, nudeći nadu za poboljšane ishode liječenja kod oboljelih od raka.
Reference
Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304. doi: 10.1177/15330338211036304
Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny AS, Moreno-Acosta P, Mery B, Rodriguez-Lafrasse C, Magne N. A review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit. 2021 Nov 3;27. doi: 10.12659/MSM.934116.
Zhuang Y, Liu K, He Q, Gu X, Jiang C, Wu J. Hypoxia signaling in cancer: Implications for therapeutic interventions. MedComm (2020). 2023 Jan 23;4(1). doi: 10.1002/mco2.203
Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G, Janji B. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: New opportunities and challenges. Cells. 2019;8(9):1083. doi: 10.3390/cells8091083.
Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015 Dec 11;3:83-92. doi: 10.2147/HP.S93413.
Chen G, Wu K, Li H, Xia D, He T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol. 2022 Sep 23;12:961637. doi: 10.3389/fonc.2022.961637.
Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234-251. doi: 10.1016/j.gendis.2023.02.039.
Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny AS, Moreno-Acosta P, Mery B, Rodriguez-Lafrasse C, Magne N. A review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit. 2021 Nov 3;27 doi: 10.12659/MSM.934116.
Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Semin Cancer Biol. 2024;98:19-30. doi: 10.1016/j.semcancer.2023.11.006. ISSN 1044-579X.
Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair (Amst). 2015 Aug;32:180-189. doi: 10.1016/j.dnarep.2015.04.030.
Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22(11):5703. doi: 10.3390/ijms22115703.
Greco O, Patterson AV, Dachs GU. Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res. 2000;41:201-212.
Chen SY, Tsuneyama K, Yen MH, Lee JT, Chen JL, Huang SM. Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer. Sci Rep. 2021 Jun 8;11(1):12033. doi: 10.1038/s41598-021-91454-2.
Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer--a review. Target Oncol. 2012 Dec;7(4):233-42. doi: 10.1007/s11523-012-0233-x.
Telarovic I, Wenger RH, Pruschy M. Interfering with tumor hypoxia for radiotherapy optimization. J Exp Clin Cancer Res. 2021 Jun 21;40(1):197. doi: 10.1186/s13046-021-02000-x.
Gao HQ, Wan YZ, Bu XM, Fan XY, Xie XX, Ji XN, Song W. How to deal with the relationship between hypoxia and radiotherapy in the hypofractionated radiotherapy era? Int J Radiat Res. October 2021;19(4):759-769. doi: 10.29242/ijrr.19.4.759.
Moon EJ, Petersson K, Olcina MM. The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. Int J Radiat Biol. 2022;98(3):439-451. doi: 10.1080/09553002.2021.1988178.
Le QT, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev. 2008 Sep;27(3):351-62. doi: 10.1007/s10555-008-9144-9.
Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014 Oct 1;21(10):1516-54. doi: 10.1089/ars.2013.5378.
Le QT, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev. 2008 Sep;27(3):351-62. doi: 10.1007/s10555-008-9144-9.
Chiari G, Fiandaca G, Delitala ME. Hypoxia-related radiotherapy resistance in tumors: treatment efficacy investigation in an eco-evolutionary perspective. Front Appl Math Stat. 2023 Jul 13;9. doi: 10.3389/fams.2023.1193191.
Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018 Oct 4;13:6049-6058. doi: 10.2147/IJN.S140462.
Musleh Ud Din S, Streit SG, Huynh BT, Hana C, Abraham A-N, Hussein A. Therapeutic targeting of hypoxia-inducible factors in cancer. Int J Mol Sci. 2024;25(4):2060. doi: 10.3390/ijms25042060.
Chen Z, Han F, Du Y, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther. 2023;8:70. doi: 10.1038/s41392-023-01332-8.
Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Semin Cancer Biol. 2024;98:19-30. doi: 10.1016/j.semcancer.2023.11.006. ISSN 1044-579X.
Preuzimanja
Objavljeno
Broj časopisa
Rubrika
Kategorije
Licenca
Autorska prava (c) 2024 Sara Morović (Autor)

This work is licensed under a KreativniCommons Attribution-NonCommercial Međunarodne licence.
HDRT